Division of Pediatric Surgery, Morgan Stanley Children's Hospital of New York-Presbyterian and Columbia University Medical Center, New York, NY 10032, USA.
J Pediatr Surg. 2010 Jan;45(1):84-7; discussion 87-8. doi: 10.1016/j.jpedsurg.2009.10.014.
Intestinal failure (IF)-associated liver disease (IFALD) complicates the treatment of children with IF receiving parenteral nutrition (PN). We hypothesized that prevention or resolution of IFALD was possible in most children and that this would result in improved outcomes.
We reviewed prospectively gathered data on all children referred to the intestinal rehabilitation and transplantation center at our institution. Total bilirubin level (TB) was used as the marker for IFALD. Patients were grouped based on TB at referral and at subsequent inpatient stays and outpatient visits. Standard treatment consisted of cycling of PN, limiting lipid infusion, enteral stimulation, use of ursodeoxycholic acid, and surgical intervention when necessary. Outcomes such as mortality, dependence on PN, and need for transplantation were assessed. Statistical analyses were performed using Fisher's exact, Mann-Whitney U, and Wilcoxon signed rank tests.
Ninety-three patients with intestinal failure and on PN were treated at our center from 2003 to 2009. Median age at referral was 5 months (0.5-264 months). Prematurity was a complicating factor in 63 patients and necrotizing enterocolitis was the most common diagnosis. Eighty-two children had short bowel syndrome, whereas the remaining 11 had extensive motility disorders. 97% of children required significant alteration of their PN administration. At referral, 76 of 93 children had TB 2.0 mg/dL or higher, and 17 had TB below 2.0 mg/dL. TB normalized in 57 of 76 children with elevated TB at referral, and TB remained elevated in 19. Normalization of TB was associated with a mortality of 5.2%, and transplantation was needed in 5.2%. Conversely, when TB remained elevated, mortality was 58% (P = .0002 vs TB normalized), and transplantation occurred in 58% owing to failure of surgical and medical rehabilitation.
Most children referred for treatment of IF have IFALD. A dedicated IF rehabilitation program can reverse IFALD in many children, and this is associated with improved outcome.
肠衰竭(IF)相关的肝病(IFALD)使接受肠外营养(PN)的 IF 患儿的治疗复杂化。我们假设在大多数儿童中,IFALD 是可以预防或解决的,并且这将导致改善的结果。
我们回顾了我院肠康复和移植中心前瞻性收集的所有患儿数据。总胆红素(TB)水平被用作 IFALD 的标志物。根据转诊时和随后的住院和门诊就诊时的 TB 将患者分组。标准治疗包括 PN 循环、限制脂质输注、肠内刺激、使用熊去氧胆酸以及必要时手术干预。评估死亡率、对 PN 的依赖和移植需求等结果。使用 Fisher 精确检验、Mann-Whitney U 检验和 Wilcoxon 符号秩检验进行统计分析。
2003 年至 2009 年,我院共治疗 93 例肠衰竭并接受 PN 的患儿。转诊时的中位年龄为 5 个月(0.5-264 个月)。早产儿是 63 例患儿的合并症,坏死性小肠结肠炎是最常见的诊断。82 例患儿患有短肠综合征,而其余 11 例患儿患有广泛的运动障碍。97%的患儿需要对其 PN 治疗进行重大调整。转诊时,93 例患儿中有 76 例 TB 为 2.0mg/dL 或更高,17 例 TB 低于 2.0mg/dL。在转诊时 TB 升高的 76 例患儿中,57 例 TB 正常化,19 例 TB 仍升高。TB 正常化与死亡率为 5.2%相关,需要进行移植的有 5.2%。相反,当 TB 持续升高时,死亡率为 58%(P =.0002 与 TB 正常化相比),由于手术和医疗康复失败,需要进行移植的有 58%。
大多数接受 IF 治疗的患儿都有 IFALD。专门的 IF 康复计划可以使许多患儿的 IFALD 逆转,并且这与改善的结果相关。